Drug Trial Radar · NCT06581419
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Dec 31, 2024
Primary completion
Aug 1, 2029
Study completion Aug 1, 2029
Sponsor
- Lead sponsor
- SUNHO(China)BioPharmaceutical CO., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I: To evaluate the safety, tolerance and effectiveness of IAP0971 for the treatment of advanced malignant tumors. Phase II: Evaluation of IAP0971 therapy driver negative and PD-L1 positive (TPS≥50%) The initial treatment is effective in subjects with advanced or metastatic non-small cell lung cancer.
Conditions
- Advanced Malignant Neoplasm
- Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
IAP0971Drug
Subjects receive IAP0971, which will be administered every 3 weeks in a 3-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of adverse events (AEs) and SAEs (Phase I)Time frame: 3 months after end event visit
- Dose limiting toxicities (DLTs) (Phase I)Time frame: 21 days after first dose
- PFS in dose expansion (Phase II)Time frame: Baseline through up to 2 years or until disease progression
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.